CRON

Cronos Group Inc

Healthcare · USD

CRON

Price

$2.53

+0.80%

Cap

$957M

Earnings

3/4 beat

30d Trend

+1%

CRON
Loading chart data...
0 data pointsPowered by Brain47
52-week range51%
1.63.43

Upper half of range — momentum is positive

Analyst consensus (5 analysts)+13% to target
0 Strong Buy2 Buy2 Hold1 Sell0 Strong Sell

Target range: $2.3$3.23 (consensus: $2.86)

Consensus: Hold

Earnings history

Q4 2025

BEAT

0.02 vs 0.01

Q3 2025

BEAT

0.07 vs -0.02

Q2 2025

MISS

-0.1 vs -0.02

Q1 2025

BEAT

0.02 vs

VolatilityLow

Key macro factors

·

Global economic slowdown and inflationary pressures: The Middle East conflict driving oil prices higher and the IMF downgrading global growth forecasts could reduce consumer discretionary spending, impacting demand for cannabis products.

·

Cannabis legalization and regulatory developments: Global trends in cannabis legalization, particularly in key markets like Germany and Israel (where CRON operates), and any potential shifts in US federal cannabis restrictions, are crucial for market expansion and operational flexibility.

·

Competition and evolving consumer preferences in the cannabis market: The rapidly changing cannabis product landscape, with new innovations in vapes and edibles, requires companies like Cronos to continuously innovate and adapt to maintain market share and appeal to diverse consumer demands.

Cronos Group Inc. is a cannabinoid company that cultivates, produces, distributes, and markets cannabis products globally, including dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under brands like Spinach, Lord Jones, Lit, and Peace Naturals.

Next earnings:2026-05-07

QUANT SCORE

Building intelligence for this stock. Brain47 needs a few days of price data to calculate technical indicators and generate a full quant score.

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.

Cronos Group Inc (CRON) — Brain47 AI Score 57/100 | Analysis